That is why they YELL about the ISIS drug, because anybody who does any research sees the efficacy at less than half of AEGRs drug.
I believe you. It IS killing you. Time to dump that alias and get another one. Oh wait, you already did that.
So Adam, I see you have another alias. How is that $15 short treating you?
The way you shorted more at $25 and $30; truly nimble.
Then to announce your shorting even more at $40, $41, and $44, absolutely God-Like.
The God of losing money.
Changing directors on the board won't help it. It is too late for that. Too many things have gone wrong already. New management is needed. Swap out the entire executive management team. The sales are so atrocious it is a joke. They should have already resigned, except they can't get a job anywhere else. So they will have to be fired. We can do it sooner or later, but it will happen eventually.
Shorts like Adam continue to get killed. Bragging about how smart they were to short at $15, how they doubled their short position at $25, increased it at $30, and $35, then even more at $40 and $42. They keep pushing a bad position. If we do hit the $100/share target is year, I wonder if they will keep shorting every step of the way. It just increases the amount they will have to cover, creating more pent up demand.
So the EU approval will effectively triple the market that they are going after.
Agreed. The FDA appears to be trying to help patients by working with SRPT to get AA as quickly as possible while still ensuring defendable legal rigor.
Do not confuse "partner" meaning - when a group works diligently towards the same goal as another group - with a formal/legal partnership. They were referring to working together towards a common goal.
Wow. It must be a truly horrible stock if its shareholders have to spam other message boards begging and pleading for people to buy it.
Interestingly enough, there is another hatchet job against AEGR by Forbes. Remember that Forbes was the one who tried to skew the facts on the AMGN drug compared with the AEGR drug. Now Forbes has yet another article that is artificially against AEGR.
Do what you are doing.
Experience is the teacher of fools. (You have to learn by making mistakes).
Rest in Peace. (or "It's your funeral").
It will take time to realize that potential value. Nobody ever has 100% marketshare, so what we need to assess is what the achievable marketshare is in order to determine the valuation. Certainly 10% market penetration is very easy to do and not over the top, so the $120-$240/share valuation is definitely in play. Who knows what the total global market is that is achievable, because there is no way that all 10,000 patients will be able to get the medication at these prices. Sure maybe the EU will kick in for a lot of them, given the socialist nature of their medicine, but the US even with Obamacare won't pick up that big a tab for those without insurance. So does that mean the total market is 3/4? 1/2? Only time will tell.